Cambrian Genomics
closedBiotechnology company which uses a novel, laser based technique to synthesize dna.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
$11.2m | Series A | ||
| Total Funding | 000k | ||
Related Content
Cambrian Genomics operates in the cutting-edge field of genomics, focusing on the study and manipulation of DNA to understand and influence the genetic code that governs all living organisms. The company serves a diverse range of clients including academic researchers, pharmaceutical companies, and biotechnology firms. Cambrian Genomics leverages advanced technologies to decode and edit genomes, enabling breakthroughs in medical research, drug development, and personalized medicine. The company operates in the biotechnology and life sciences market, utilizing a business model that includes service contracts, licensing agreements, and product sales. Revenue is generated through the provision of genomic sequencing services, custom DNA synthesis, and proprietary genomic editing tools. Cambrian Genomics is at the forefront of genomic innovation, providing essential tools and services that drive advancements in understanding and manipulating genetic information.
Keywords: Genomics, DNA sequencing, genetic editing, biotechnology, life sciences, pharmaceutical research, custom DNA synthesis, personalized medicine, genomic tools, advanced research.